NCLEX Review Guide: Diphtheria in Pediatric Patients

Disease Overview

• Diphtheria is a highly contagious bacterial infection caused by Corynebacterium diphtheriae that primarily affects the respiratory tract and can produce life-threatening toxins.
• The bacteria releases an exotoxin that damages heart muscle, kidneys, and nervous system tissues, making systemic complications the primary concern.
• Disease transmission occurs through respiratory droplets and direct contact with infected secretions or contaminated objects.

Key Clinical Manifestations

• Pseudomembrane formation: Thick, gray-white, adherent membrane in throat that bleeds when removal is attempted - this is pathognomonic for diphtheria.
• Bull neck appearance: Massive cervical lymphadenopathy and neck edema creating a characteristic swollen neck appearance.
• Progressive respiratory symptoms including stridor, dyspnea, and potential airway obstruction requiring immediate intervention.
• Systemic toxin effects: myocarditis (most common cause of death), peripheral neuropathy, and acute tubular necrosis.

Priority Interventions

1. Airway assessment: Continuously monitor for signs of respiratory distress and prepare for emergency intubation or tracheostomy.
2. Implement strict droplet precautions immediately upon suspicion - private room, masks for all staff and visitors.
3. Administer diphtheria antitoxin as soon as possible after skin testing for horse serum sensitivity.
4. Begin antibiotic therapy with penicillin or erythromycin to eliminate the organism and prevent transmission.

Monitoring & Complications

• Cardiac monitoring is essential as myocarditis can develop 2-6 weeks post-infection and is the leading cause of death.
• Neurological assessments for peripheral neuropathy, which typically appears 2-12 weeks after onset and may affect cranial nerves.
• Monitor for secondary bacterial infections and maintain nutritional support due to difficulty swallowing.

Vaccination Schedule

• The DTaP vaccine (diphtheria, tetanus, acellular pertussis) is given at 2, 4, 6, and 15-18 months, with a booster at 4-6 years.
• Tdap booster is recommended at age 11-12 years, then Td boosters every 10 years throughout adulthood.
• Unvaccinated contacts require immediate prophylactic antibiotics and should begin vaccination series.

Common Pitfalls

Priority Nursing Diagnoses

• Ineffective airway clearance related to pseudomembrane formation and potential obstruction
• Risk for infection transmission related to highly contagious nature of disease
• Decreased cardiac output related to potential myocarditis from bacterial toxins